Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of “Moderate Buy” from Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been given a consensus rating of “Moderate Buy” by the eleven analysts that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $44.50.

Several equities research analysts have commented on CLDX shares. Stifel Nicolaus reiterated a “buy” rating and set a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th. The Goldman Sachs Group lifted their price target on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, January 21st. Finally, Barclays increased their price objective on Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a research note on Wednesday, December 17th.

Celldex Therapeutics Stock Up 2.9%

Shares of NASDAQ CLDX opened at $30.90 on Monday. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of -7.94 and a beta of 1.17. The company’s 50-day simple moving average is $26.64 and its 200-day simple moving average is $26.27. Celldex Therapeutics has a 52-week low of $14.40 and a 52-week high of $31.99.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The company had revenue of $0.12 million for the quarter, compared to analyst estimates of $1.53 million. Celldex Therapeutics had a negative return on equity of 41.67% and a negative net margin of 3,446.88%. Equities research analysts anticipate that Celldex Therapeutics will post -2.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

A number of hedge funds have recently modified their holdings of the business. Simplify Asset Management Inc. acquired a new position in Celldex Therapeutics during the third quarter worth about $2,199,000. Segall Bryant & Hamill LLC grew its stake in Celldex Therapeutics by 36.3% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 528,597 shares of the biopharmaceutical company’s stock valued at $13,675,000 after acquiring an additional 140,709 shares in the last quarter. American Century Companies Inc. raised its holdings in Celldex Therapeutics by 4.6% in the 3rd quarter. American Century Companies Inc. now owns 815,560 shares of the biopharmaceutical company’s stock valued at $21,099,000 after acquiring an additional 35,575 shares during the last quarter. Eventide Asset Management LLC lifted its stake in Celldex Therapeutics by 37.1% in the 3rd quarter. Eventide Asset Management LLC now owns 1,859,095 shares of the biopharmaceutical company’s stock worth $48,096,000 after purchasing an additional 502,909 shares in the last quarter. Finally, Propel Bio Management LLC purchased a new position in Celldex Therapeutics in the 3rd quarter worth approximately $4,010,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.